CAMERA: Combination antibiotic treatment for Methicillin Resistant Staphylococcus Aureus Bacteraemia - a Randomised Controlled Trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1078930

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

MRSA (golden staph) is resistant to the most useful class of antibiotics: beta-lactams. It is more difficult to treat than antibiotic-sensitive strains. Standard treatment for MRSA is vancomycin but it has high failure rates. Although MRSA is resistant to beta-lactams, lab studies show that they enhance vancomycin’s bacterial killing when used together. CAMERA2 is an RCT comparing vancomycin alone to combination therapy (vancomycin plus flucloxacillin) for adults with MRSA blood stream infection

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $1,162,248.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Microbiology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Staphylococcus aureus | antibiotic resistance | antibiotics | infection | sepsis

Related Links